These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25997494)

  • 41. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
    Desrosiers RR; Cusson MH; Turcotte S; Béliveau R
    Int J Cancer; 2005 May; 114(5):702-12. PubMed ID: 15609318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.
    Baker EA; Leaper DJ
    Eur J Cancer; 2003 May; 39(7):981-8. PubMed ID: 12706368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer.
    Surlin V; Ioana M; Pleşea IE
    Rom J Morphol Embryol; 2011; 52(1 Suppl):231-6. PubMed ID: 21424059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect.
    Maupas-Schwalm F; Bedel A; Augé N; Grazide MH; Mucher E; Thiers JC; Salvayre R; Nègre-Salvayre A
    Cell Signal; 2009 Dec; 21(12):1925-34. PubMed ID: 19735728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-invasion effect of crebanine and O-methylbulbocapnine from Stephania venosa via down-regulated matrix metalloproteinases and urokinase plasminogen activator.
    Yodkeeree S; Wongsirisin P; Pompimon W; Limtrakul P
    Chem Pharm Bull (Tokyo); 2013; 61(11):1156-65. PubMed ID: 23985774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The expression of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and angiogenesis in relation to the depth of tumor invasion and lymph node metastasis in submucosally invasive colorectal carcinoma].
    Jung SA; Yang SK; Kim JS; Shim KN; Im SA; Myung SJ; Jung HY; Yu CS; Kim JC; Hong WS; Kim JH; Min YI
    Korean J Gastroenterol; 2005 Jun; 45(6):401-8. PubMed ID: 15973074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intracellular localization of matrix metalloproteinases and their inhibitors in cultured tumor cell lines: flow cytometric analysis.
    Koyama S
    Oncol Rep; 2006 Mar; 15(3):735-8. PubMed ID: 16465438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of MMP-2 and MMP-9 secretion by cytokines, inducers and inhibitors in human glioblastoma T-98G cells.
    Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A
    Oncol Rep; 2017 Mar; 37(3):1907-1913. PubMed ID: 28112361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours.
    Giantin M; Aresu L; Benali S; Aricò A; Morello EM; Martano M; Vascellari M; Castagnaro M; Lopparelli RM; Zancanella V; Granato A; Mutinelli F; Dacasto M
    J Comp Pathol; 2012 Nov; 147(4):419-29. PubMed ID: 22520817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
    Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
    Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study.
    Hirano H; Tsuji M; Kizaki T; Sashikata T; Yoshi Y; Okada Y; Mori H
    Med Electron Microsc; 2002 Mar; 35(1):16-23. PubMed ID: 12111403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matrix metalloproteinases and their tissue inhibitors in the developing neonatal mouse uterus.
    Hu J; Zhang X; Nothnick WB; Spencer TE
    Biol Reprod; 2004 Nov; 71(5):1598-604. PubMed ID: 15240428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway.
    Kimata M; Ishizaki M; Tanaka H; Nagai H; Inagaki N
    Allergol Int; 2006 Mar; 55(1):67-76. PubMed ID: 17075289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Regulation of matrix-degrading enzymes in gynecologic cancer tissues and cells].
    Kikkawa F
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):618-22. PubMed ID: 8808829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Photodynamic therapy down-regulates the invasion promoting factors in human oral cancer.
    Sharwani A; Jerjes W; Hopper C; Lewis MP; El-Maaytah M; Khalil HS; Macrobert AJ; Upile T; Salih V
    Arch Oral Biol; 2006 Dec; 51(12):1104-11. PubMed ID: 16889746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
    Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Involvement of matrix metalloproteinase 1 and urokinase-type plasminogen activator in the PKCα-p38 MAPK pathway-mediated progression of human liver cancer cells.
    Ye JC; Hsieh YS; Chen PN; Liu JY; Hsieh YH
    Drug Dev Res; 2023 Jun; 84(4):767-776. PubMed ID: 37005497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines.
    Gach K; Wyrebska A; Szemraj J; Janecka A
    Mol Biol (Mosk); 2012; 46(6):894-9. PubMed ID: 23350235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer.
    Groblewska M; Siewko M; Mroczko B; Szmitkowski M
    Folia Histochem Cytobiol; 2012 Apr; 50(1):12-9. PubMed ID: 22532131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.